Methanocarba cycloakyl nucleoside analogues

Details Methanocarba cycloakyl nucleoside analogues Methanocarba cycloakyl nucleoside analogues

2006-08-08

2006-08-08

Berch, Mark L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C544S244000, C544S276000, C544S277000, C514S263400, C514S263370

Reexamination Certificate

active

07087589

ABSTRACT:
The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloakyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B, A3, P2Y2receptors), cancer (through A3, P2 receptors), cardiac arrhythmias (through A1receptors), cardiac ischemia (through A1, A3receptors), epilepsy (through A1, P2X receptors), and Huntington's Disease (through A2Areceptors).

REFERENCES:
patent: 2577706 (1951-12-01), Hotten
patent: 3146211 (1964-08-01), Errede
patent: 3984406 (1976-10-01), Quadbeck-Seeger et al.
patent: 4048171 (1977-09-01), Bossert et al.
patent: 4072633 (1978-02-01), Hermans
patent: 4548818 (1985-10-01), Kjellin et al.
patent: 4659717 (1987-04-01), Wikel
patent: 4672068 (1987-06-01), Kutsuma et al.
patent: 4772607 (1988-09-01), Badger et al.
patent: 4866072 (1989-09-01), Edwards et al.
patent: 4954504 (1990-09-01), Chen et al.
patent: 5032593 (1991-07-01), Rzeszotarski et al.
patent: 5063233 (1991-11-01), Chen et al.
patent: 5096916 (1992-03-01), Skupin
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5270316 (1993-12-01), Suzuki et al.
patent: 5284834 (1994-02-01), Jacobson et al.
patent: 5310731 (1994-05-01), Olsson et al.
patent: 5366977 (1994-11-01), Pollard et al.
patent: 5443836 (1995-08-01), Downey et al.
patent: 5498605 (1996-03-01), Jacobson et al.
patent: 5620676 (1997-04-01), Jacobson et al.
patent: 5629454 (1997-05-01), Marquez et al.
patent: 5688774 (1997-11-01), Jacobson et al.
patent: 5773423 (1998-06-01), Jacobson et al.
patent: 5840728 (1998-11-01), Marquez et al.
patent: 5877179 (1999-03-01), Pollard et al.
patent: 6066642 (2000-05-01), Jacobson et al.
patent: 2004/0142946 (2004-07-01), Chattopadhyaya
patent: 0 217 530 (1987-04-01), None
patent: 0 374 808 (1990-06-01), None
patent: 0 577 558 (1994-01-01), None
patent: WO 94/03456 (1994-02-01), None
patent: WO 94/25605 (1994-11-01), None
patent: WO 94/25607 (1994-11-01), None
patent: WO 95/03304 (1995-02-01), None
patent: WO 95/08541 (1995-03-01), None
patent: WO 96/16084 (1996-05-01), None
patent: WO 97/27177 (1997-07-01), None
patent: WO 98/05662 (1998-02-01), None
Suzuki, et al., J. Med. Chem. 35(19), 3578-3581.
Nair et al Tetrahedron 49(11), 2169 (1993).
Sluggett, J. Amer. Chem Soc. 117, 5148-5153 (1995).
Lopin, J. Org. Chem.; 2003; 68(26) pp. 9916-9923.
Sumiyoshi, Die Makromolekulare Chemie vol. 186, Issue 9 , pp. 1811-1823 (1985).
Ruan, Journal of Applied Polymer Science vol. 92, Issue 3 , pp. 1618-1624 (2004).
S. V. Kononova, Biochemistry (Moscow), vol. 67, No. 2 (2002) 184-195.
Turro, Chemical Physics Letters 193, 546 (1992).
Miriam Webster Online Dictionary definition for phosphoryl <http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=phosphoryl> downloaded from the Internet Feb. 23, 2004.
Gong, Heteroatom Chemistry vol. 14, Issue 1 , pp. 13-17 (2003).
“phosphonic acids” http://www.chemsoc.org/chembytes/goldbook/P04560.PDF downloaded from the Internet May 31, 2005.
Hackh's Chemical Dictionary, 5th edition, 1987, pp. 444.
Registry File for RN 129687-40-7.
Registry File for RN 146038-94-0.
Registry File for RN 159967-50-7.
Jacobson et al., “Synthesis and Biological Activity of N6-(p-Sulfophenyl)alkyl and N6-Sulfoalkyl Derivatives of Adenosine: Water-soluble and Peripherally Selective Adenosine Agonists”, Journal of Medicinal Chemistry, 35(22), 4143-4149 (1992).
Carruthers et al., “Adenosine A3receptors: two into one won't go”, Reprinted from Trends in Pharmacological Sciences, 14(8), 290-291 (Aug. 1993).
Van Galen et al., “Xanthine-7-Ribosides as Adenosine Receptor Antagonists: Further Evidence for Adenosine's Anti Mode of Binding”, Cleosides & Nucleotides, 10(5), 1191-1193 (1991).
Von Lubitz et al., “Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1receptor agonist”, European Journal of Pharmacology, 54886, 1-6 (1996).
Jacobson et al., “8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo”, FEBS LETTERS, 323(1,2), 141-144 (May 1993).
Van Bergen et al., “A3Receptors: Structure-Activity Relationships and Molecular Modeling”, Abstract of American Chemical Society Meeting, Chicago, Illinois (Aug. 25, 1993).
Fozard et al., “Adenosine A3receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat”, Special Report, Br. J. Pharmacol., 109, 3-5 (1993).
De et al., “Differential Distribution of A3Receptor in Rat Brain ”, Society for Neuroscience Abstracts, 19 (1993), #42.11.
Bruns et al., “Characterization of the A2Adenosine Receptor Labeled by3H]NECA in Rat Striatal Membranes”, Olecular Pharmacology, 2, 331-346 (1986).
Jacobson et al., “Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential”, Journal of Medicinal Chemistry, 35(3), 407-422 (1992).
Jacobson et al., “Stimulation by Alkylxanthines of Chloride Efflux in DFPAC-1 Cells does not Involve A1Adenosine Receptors” Biochemistry, 34, 9088-9094 (1995).
Brackett et al., “Activities of Caffeine, Theophylline, and Enprofylline Analogs as Tracheal Relaxants”, Biochemical Pharmacology, 39(12), 1897-1904 (1990).
Alzheimer et al., “Transient and selective blockade of adenosine A1-receptors by 8-cyclopentyl-1,3-dipropylaxanthine (DPCPX) causes sustained epileptiform activity in hippocampal CA3 neurons of guinea pigs”, Neuroscience Letters, 99(1,2), 107-112 (1989).
Daly, “Mechanism of Action of Caffeine”, Caffeine, Coffee, and Health, edited by S. Garatini, Published by Raven Press, Ltd., New York, 97-150 (1993).
Bruns et al., “Role of Adenosine in Energy Supply/Demand Balance”, Nucleosides & Nucleotides, 10(5), 931-943 (1991).
Bruns et al., “Adenosine receptors in brain membranes: Binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine”, Proc. Natl. Acad. Sci., 77(9), 5547-5551 (Sep. 1980).
Jacobson et al., “Development of Selective Purinoceptor Agonists and Antagonists”, Purinergic Approaches in Experimental Therapeutics, Chapter 6, 101-128 (1997).
Zhou et al., “Molecular cloning and characterization of an adenosine receptor: The A3adenosine receptor”, Proc. Natl. Acad. Sci., 89, 7432-7436 (Aug. 1992).
Ramkumar et al., “The A3Adenosine receptor is the Unique Adenosine Receptor which Facilitates Release of Allergic Mediators in Mast Cells”, 16887-16889 (Jun. 7, 1993).
Ali et al., “Sustained activation of phospholipase D via adenosine A3receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line”, JPET-Abstracts, 276(2), 837-845 (1996).
Von Lubitz et al., “Adenosine A3receptor stimulation and cerebral ischemia”, European Journal of Pharmacology, 263, 59-67 (1994).
Van Rhee et al., “Interaction of 1,4-Dihydropyridine and Pyridine Derivatives with Adenosine Receptors: Selectivity for A3Receptors”, J. Med. Chem., 39, 2980-2989 (1996).
Jiang et al., 6-Phenyl-1,4-dihydropyridine Derivatives as Potent and Selective A3Adenosine Receptor Antagonists, J. Med. Chem., 39, 4667-4675 (1996).
Jiang et al., “Structure-Activity Relationships of 4-(Phenylethynyl)-6-phenyl-1,4-dihydropyridines as Highly Selective A3Adenosine Receptor Antagonists”, Med. Chem., 40, 2596-2608 (1997).
Kim et al., “Derivatives of the Triazoloquinazoline Adenosine Antagonist (CGS15943) Are Selective for the Human A3Receptor Subtype”, J. Med. Chem., 39, 4141-4148 (1996).
Karton et al., “Synthesis and Biological Activities of

Affiliated with

Also associated with

Rating

Methanocarba cycloakyl nucleoside analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methanocarba cycloakyl nucleoside analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methanocarba cycloakyl nucleoside analogues will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3640269